CASE STUDY

Microsimulation cost-effectiveness model for health technology assessment (HTA)

The challenge

Capturing the full value of new treatments in complex, heterogeneous therapeutic areas (such as obesity) is challenging with cohort models. Our client needed an economic model which seamlessly integrated a wealth of disparate clinical data, in a fully probabilistic cost-effectiveness analysis for CADTH submission.

Our approach

- Designed a novel microsimulation model based on our clients existing cohort model.
- Conducted a systematic review, and engaged with key experts, and extensively analysed trial data and literature to inform disease progression risk equations.
- Adaptable Excel models, aligned to CADTH and NICE standards, enabling simulation of alternate scenarios.
- Technical support documentation to enable easy modification in future.

How we made a difference

- We developed a complex model, with meticulous alignment to submission needs. The model was capable of fully capturing our client's product value, and we ensured that our client and key stakeholders understood the key health economic considerations.

WICKENSTONES
PARTNERS IN BUILDING VALUE